Connect Biopharma Holdings Limited reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its principal program is rademikibart, an antibody designed to target interleukin-4-receptor alpha, with company updates centered on asthma, chronic obstructive pulmonary disease and moderate-to-severe atopic dermatitis.
Recurring news includes rademikibart clinical data, Seabreeze STAT asthma and COPD study updates, Data Monitoring Committee and regulatory-related disclosures, partner activity involving Simcere in China, financial results, financing activity, investor conference participation and governance matters.
Connect Biopharma (Nasdaq: CNTB) agreed to sell 6,130,000 ordinary shares in a private placement at $3.25 per share, expected to raise gross proceeds of approximately $20.2 million.
The financing, led by Panacea Venture with Leerink Partners and Cantor as joint placement agents, is expected to close on or about March 31, 2026 and extend the company’s cash runway into the second half of 2027. Net proceeds will fund R&D, development programs, working capital and general corporate purposes.
Connect Biopharma (Nasdaq: CNTB) reported Phase 3 RADIANT-AD results for rademikibart, presented at AAD 2026. In a 52-week trial (n=259), rademikibart achieved durable responses: EASI-75 96.6%, IGA 0/1 87.1%, and EASI-90 85.3%, with safety comparable to placebo and low conjunctivitis rates.
The study used 300 mg SC every two weeks with a 16-week induction and 36-week maintenance phase; company to host a March 30, 2026 webcast and call.
Connect Biopharma (Nasdaq: CNTB) reported positive topline Phase 1 results for IV rademikibart (300 mg 2-minute IV push) in asthma and COPD patients on March 30, 2026. Patients showed rapid FEV1 gains (≥200 mL in many) within 15 minutes, with mean improvements ~200–400 mL maintained through Day 29. The drug was generally well tolerated with no serious or severe AEs. Connect is recruiting Phase 2 Seabreeze STAT studies for acute exacerbations and expects topline Phase 2 data mid-2026, then plans FDA discussions on a Phase 3 program.
Connect Biopharma (Nasdaq: CNTB) announced that results from a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis, conducted by partner Simcere, will be presented in the Late-Breaking Research session at the AAD Annual Meeting on March 28, 2026.
The presentation (RADIANT-AD) is scheduled for March 28, 2026, 9:48–10:00 a.m. MDT at Bellco Theatre 3. According to Connect Biopharma, the Phase 3 data provide a strong basis for Simcere’s pending NDA in China and highlight rademikibart’s potentially differentiated safety and efficacy, supporting future AD development outside China.
Connect Biopharma (Nasdaq: CNTB) management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
A live webcast will be available via the company investor website and an archived replay will remain accessible for approximately 90 days.
Connect Biopharma (Nasdaq: CNTB) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast will be available via the Investors section of the company website at investors.connectbiopharma.com, with an archived replay accessible for approximately 90 days after the conference.
Connect Biopharma (Nasdaq: CNTB) highlighted new mechanism‑of‑action data for rademikibart and outlined 2026 priorities, emphasizing clinical execution. Mechanistic studies show enhanced IL‑4R binding, greater internalization versus dupilumab, and stronger rescue of β‑agonist responsiveness in human airway models, supporting faster, larger FEV1 improvements observed previously. Ongoing Phase 1b IV study has shown preliminary faster FEV1 increases versus subcutaneous dosing with topline results expected in Q1 2026. Phase 2 Seabreeze STAT asthma and COPD trials are recruiting with topline data expected mid‑2026. Cash, cash equivalents and short‑term investments were $54.8M as of Sept 30, 2025, with runway into 2027 under current plans.
Connect Biopharma (Nasdaq: CNTB) announced that company management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 10:50 a.m. ET.
A live webcast will be available via the company's Investors website at investors.connectbiopharma.com, and an archived replay will be accessible on the site for approximately 90 days after the conference.
Connect Biopharma (Nasdaq: CNTB) reported third quarter 2025 results and a business update on Nov 12, 2025. Key developments include ongoing recruitment in Phase 2 Seabreeze STAT studies for acute asthma and COPD with topline data expected in 1H 2026, and presentation of positive Phase 2 asthma data at ERS 2025 showing larger lung-function gains in patients with baseline EOS ≥300 cells/μL and FeNO ≥25 ppb. Connect’s Greater China licensee, Simcere, had its NDA for rademikibart in atopic dermatitis accepted by China’s NMPA in July 2025; Connect is eligible for up to $110 million of remaining milestone payments plus tiered royalties. Corporate actions included terminating the ADR program and directly listing ordinary shares on Nasdaq under CNTB. Cash and short-term investments were $54.8M at Sept 30, 2025, expected to fund operations into 2027.
Connect Biopharma (NASDAQ:CNTB) presented promising data for rademikibart, their investigational anti-IL-4Rα antibody, at the European Respiratory Society Congress 2025. The Phase 2b trial results showed significant improvements in lung function and asthma control, particularly in patients with elevated type 2 inflammatory markers.
Key findings include a 507 mL improvement in prebronchodilator FEV1 at Week 24 in patients with high EOS and FeNO levels, and substantial reductions in asthma exacerbations (63% reduction in high EOS patients and 69% reduction in high FeNO patients). The company expects to report topline data from ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD in 1H 2026.